

## Oncology Today with Dr Neil Love: Key Presentations on Breast Cancer from the 2022 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following subgroups of patients with ER+/HER2- advanced breast cancer had a significant overall survival and progression-free survival benefit with addition of capivasertib to fulvestrant compared to fulvestrant and placebo in the FAKTION trial?
  - Only patients with alterations in the PI3K/AKT/PTEN pathway
  - Only patients without alterations in the PI3K/AKT/PTEN pathway
  - Patients with and without alterations in the PI3K/AKT/PTEN pathway
- Which of the following results was reported at ASCO 2022 from the PALOMA-2 trial of palbociclib with letrozole versus placebo with letrozole for postmenopausal women with ER+/HER2- advanced breast cancer?
  - There was a significant improvement in median overall survival with palbociclib
  - There was no significant improvement in median overall survival with palbociclib
- Which of the following results was reported at ASCO 2022 from the Phase III ASCENT trial of sacituzumab govitecan versus chemotherapy of physician's choice for relapsed or refractory metastatic triple-negative breast cancer?
  - Sacituzumab govitecan was not superior to chemotherapy
  - Sacituzumab govitecan was superior to chemotherapy in the brain met-negative population only
  - Sacituzumab govitecan was superior to chemotherapy in the brain met-negative and ITT populations
- In the expanded safety review of the DESTINY-Breast03 trial comparing T-DXd to T-DM1, which of the following adverse events was more common with T-DXd than with T-DM1?
  - Nausea
  - Vomiting
  - Alopecia
  - All of the above
- Which of the following is the target of the novel antibody-drug conjugate patritumab deruxtecan?
  - LIV-1
  - HER2
  - HER3
  - TROP-2